MedCity News October 30, 2024
After the FDA delayed the approval of MDMA-assisted therapy for PTSD, there’s still a way forward for psychedelic medicines, experts said at HLTH.
After the Food and Drug Administration’s recent decision to delay the approval of MDMA-assisted therapy for post-traumatic stress disorder, the path forward has become less straightforward for the field of psychedelic medicines. But this isn’t the end of the road, according to a panel of experts last week at the HLTH 2024 conference in Las Vegas.
The new drug application was submitted by Lykos Therapeutics and would have been the first new treatment option for PTSD in over two decades, according to the company. The drug would have been provided with talk therapy. The FDA requested in...
Today's Sponsors
Today's Sponsor